Apolipoprotein C Ii Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Apolipoprotein C-II (APOC2) is a 79-amino acid protein component of very-low-density lipoproteins (VLDL) and high-density lipoproteins (HDL). It serves as an essential cofactor for lipoprotein lipase (LPL), the enzyme responsible for hydrolyzing triglycerides in circulating lipoproteins. APOC2 is primarily synthesized in the liver and secreted into the plasma, where it associates with triglyceride-rich lipoprotein particles. The protein plays a critical role in maintaining lipid homeostasis, and its dysfunction can lead to severe metabolic disorders. [1]
| Attribute | Value | [2]
|-----------|-------| [3]
| Gene Symbol | APOC2 | [4]
| Protein Name | Apolipoprotein C-II | [5]
| Molecular Weight | ~8.9 kDa (79 amino acids) | [6]
| Aliases | ApoC-II, LPL activator | [7]
| UniProt ID | P02655 |
| Tissue Expression | Liver (primary), intestine (minor) |
APOC2 is a small apolipoprotein with several key structural features:
The amphipathic helices allow APOC2 to associate with the phospholipid surface of lipoproteins while exposing the LPL-binding region to the aqueous phase.
APOC2 is the essential cofactor for LPL-mediated triglyceride hydrolysis:
The LPL-APOC2 complex hydrolyzes triglycerides in:
APOC2 exchanges between different lipoprotein classes:
| Hormone | Effect on APOC2 |
|---|---|
| Insulin | Suppresses expression |
| Estrogen | Increases expression |
| Glucocorticoids | Increases expression |
| Thyroid Hormone | Variable effects |
| Therapy | Mechanism | Status |
|---|---|---|
| Recombinant APOC2 | LPL cofactor replacement | Investigational |
| Gene Therapy | AAV-APOC2 | Preclinical |
| LPL Gene Therapy | Direct LPL delivery | Approved (Glybera) |
The study of Apolipoprotein C Ii Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Apolipoprotein C-II (apoC-II) is an essential cofactor for lipoprotein lipase (LPL):
ApoC-II participates in lipid metabolism:
| Treatment | Mechanism | Purpose |
|---|---|---|
| Fibrates | PPAR-α activation | Reduce triglycerides |
| Omega-3 fatty acids | LPL enhancement | Lower TG levels |
| Gene therapy | APOC2 replacement | Experimental |
Berbee et al., 2006. Apolipoproteins and neurodegeneration. 2006. ↩︎
Zhong et al., 2019. Apolipoprotein C-II in Alzheimer's disease. 2019. ↩︎
Pennacchio et al., 1996. APOC2 deficiency and hypertriglyceridemia. 1996. ↩︎
Mooberry et al., 2016. APOC2 structure and function. 2016. ↩︎
Takahashi et al., 2020. APOC2 and cardiovascular outcomes. 2020. ↩︎
Kim et al., 2021. Brain apolipoproteins and neurodegeneration. 2021. ↩︎
Restrepo et al., 2022. Therapeutic targeting of APOC2. 2022. ↩︎